AR071688A1 - Derivados de pirrol, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de pirrol, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR071688A1 AR071688A1 ARP090101646A ARP090101646A AR071688A1 AR 071688 A1 AR071688 A1 AR 071688A1 AR P090101646 A ARP090101646 A AR P090101646A AR P090101646 A ARP090101646 A AR P090101646A AR 071688 A1 AR071688 A1 AR 071688A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- unsubstituted
- substituted
- independently selected
- atom
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000005843 halogen group Chemical group 0.000 abstract 11
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 10
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 10
- 125000001153 fluoro group Chemical group F* 0.000 abstract 10
- -1 homopiperidin-1-yl Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 10
- 229910052731 fluorine Inorganic materials 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 3
- 150000003254 radicals Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Reivindicacion 1: Compuesto de formula (1) en la que A representa un grupo alquileno C1-6 no sustituido o sustituido una o varias veces con un grupo alquilo C1-3 o un tomo de fluor; R1 representa un tomo de hidrogeno o un grupo alquilo C1-4 no sustituido o sustituido con uno o varios tomos de fluor; R2 representa bien un radical homopiperidin-1-ilo, piperidin-1-ilo, pirrolidin-1-ilo o azetidin-1-ilo, estando dichos radicales no sustituidos o sustituidos una o dos veces con un sustituyente elegido cada uno independientemente entre un tomo de fluor, un grupo alcoxi C1-4, alquilo C1-4, trifluorometilo, -OCF3, -CH2OH, -CONH2 y/o un grupo fenilo, estando dicho grupo fenilo no sustituido o sustituido una o dos veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo -CF3, un grupo metoxi y/o un grupo trifluorometoxi; bien un grupo amino alquilo C1-6 no sustituido o sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un tomo de fluor, un grupo hidroxilo, -CONH2 y/o un grupo fenilo, estando dicho grupo fenilo no sustituido o sustituido una o dos veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo -CF3, un grupo metoxi y/o un grupo trifluorometoxi; o R1 y R2 junto con el tomo de nitrogeno al que est n unidos constituyen bien un radical piperazin-1-ilo o 1,4-diazepan-1-ilo, estando dichos radicales no sustituidos o sustituidos con un grupo fenilo, benzodioxolilo, benzodioxolilmetilo, tetrahidrofuranilcarbonilo, -COR11 y/o -CH2COR11; estando el grupo fenilo el mismo no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo alquilo C1-4, trifluorometilo, hidroxilo, alcoxi C1-4 y/o ciano; bien un radical homopiperidin-1-ilo, piperidin-1-ilo, pirrolidin-1-ilo o azetidin-1-ilo, estando dichos radicales no sustituidos o sustituidos una o dos veces con un sustituyente elegido cada uno independientemente entre: un tomo de fluor, un grupo ciano, -COR11, -CONR12R13, -NR12R13, -NHCOR14, -CH2COR11, -SO2R14; y/o -SO2NR12R13; y/o un grupo alquilo C1-4 no sustituido o sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un tomo de halogeno y/o hidroxilo, y/o un grupo fenilo, piridinilo; estando dichos grupos no sustituidos o sustituidos una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo alquilo C1-4, trifluorometilo, hidroxilo, alcoxi C1-4 y/o ciano; y/o un grupo bencilo no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo alquilo C1-4, trifluorometilo, hidroxilo, alcoxi C1-4 y/o ciano; y/o un grupo piperidin-1-ilo, pirrolidin-1-ilo, azetidin-1-ilo, estando dichos grupos no sustituidos o sustituidos una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de fluor, un grupo alquilo C1-4, alcoxi C1-4, hidroxilo, trifluorometilo y/o -OCF3; y/o un grupo aminofenilo, aminobencilo, estando dichos grupos no sustituidos o sustituidos una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo metilo, trifluorometilo, hidroxilo, alcoxi C1-4 y/o ciano; y/o un grupo amino-cicloalquilo C3-7 no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo hidroxilo, alquilo C1-4, alcoxi C1-4 y/o ciano, estando dicho grupo alquiIo C1-4 no sustituido o sustituido una o varias veces con un tomo de fluor; R3, R4, R5, R6, R7, R8 representan cada uno independientemente un tomo de hidrogeno, un tomo de halogeno, un grupo -CN, S(O)nR14, -OS(O)nR14, un grupo alquilo C1-6 no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de fluor, un grupo -OH, -OR14, -S(O)nR14, -OSO2R14 y/o -NHSO2R14, o un grupo alcoxi C1-6, no sustituido o sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un tomo de fluor, un grupo -OH, -OR14, -S(O)nR14, -OSO2R14 y/o -NHSO2R14; R9 representa un grupo -OR12, -CN, -CO2H, NR12R13, -CONR12R13, NR15COR12, CONHNH2, -CONHOH, -CONHSO2R14, -S(O)nR14, -SO2NR12R13, -NR18SO2R14, -NR15SO2NR12R13, o un heterociclo arom tico elegido entre el grupo de formulas (2), R10 representa un hidrogeno o un grupo alquilo C1-4; R11 representa un grupo alquilo C1-4, fenilo, bencilo, alcoxi C1-4 o alquileno C1-3-alquilo C1-3-O-; estando dichos grupos no sustituidos o sustituidos con uno o varios sustituyentes elegidos cada uno independientemente entre un grupo alcoxi C1-4, un grupo hidroxi y/o uno o varios tomos de fluor; un trifluorometilo; y/o un grupo NR16R17; R12 y R13 representan cada uno independientemente un tomo de hidrogeno o un grupo alquilo C1-6 opcionalmente sustituido con uno o varios sustituyentes elegidos cada uno independientemente entre un tomo de halogeno, un grupo cicloalquilo C3-7, ciano, -OH y/o -OR14, o R12 y R13 junto con el tomo de nitrogeno al que est n unidos constituyen un radical heteroc¡clico de 4 a 7 eslabones que puede comprender un segundo hetero tomo elegido entre un tomo de nitrogeno, de ox¡geno o de azufre; n representa 0, 1 o 2; R14 representa un grupo alquilo C1-4 no sustituido o sustituido con uno o varios tomos de fluor; R15 representa un tomo de hidrogeno o un grupo alquilo C 1-4; R16 y R17 representan cada uno independientemente un tomo de hidrogeno; y/o un grupo bencilo no sustituido o sustituido una o varias veces con un sustituyente elegido cada uno independientemente entre un tomo de halogeno, un grupo metilo, trifluorometilo, hidroxilo, alcoxi C1-4 y/o ciano; y/o un grupo alquilo C1-6 opcionalmente sustituido con uno o varios tomos de halogeno, grupos -OH, y/o -OR14; R18 representa un tomo de hidrogeno o un grupo alquilo C1-4 no sustituido o sustituido con uno o varios tomos de fluor; o su sal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0802552A FR2930939B1 (fr) | 2008-05-09 | 2008-05-09 | Derives de pyrrole, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071688A1 true AR071688A1 (es) | 2010-07-07 |
Family
ID=39930534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101646A AR071688A1 (es) | 2008-05-09 | 2009-05-07 | Derivados de pirrol, su preparacion y su aplicacion en terapeutica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8680102B2 (es) |
| EP (1) | EP2283007A2 (es) |
| JP (1) | JP5611193B2 (es) |
| AR (1) | AR071688A1 (es) |
| FR (1) | FR2930939B1 (es) |
| PA (1) | PA8825701A1 (es) |
| PE (1) | PE20091830A1 (es) |
| TW (1) | TW200951120A (es) |
| UY (1) | UY31814A (es) |
| WO (1) | WO2009141532A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180022698A1 (en) | 2014-10-16 | 2018-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
| IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2023089612A1 (en) * | 2021-11-19 | 2023-05-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271176B2 (en) | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| MXPA04002438A (es) | 2001-09-24 | 2004-06-29 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad. |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0403780D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Therapeutic agents |
| FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
| FR2882054B1 (fr) * | 2005-02-17 | 2007-04-13 | Sanofi Aventis Sa | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique |
| FR2887548B1 (fr) * | 2005-06-27 | 2007-09-21 | Sanofi Aventis Sa | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
| MX2008016338A (es) * | 2006-06-27 | 2009-01-16 | Abbott Lab | Derivados de pirrol y sus metodos de uso. |
| FR2908766B1 (fr) * | 2006-11-20 | 2009-01-09 | Sanofi Aventis Sa | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
-
2008
- 2008-05-09 FR FR0802552A patent/FR2930939B1/fr not_active Expired - Fee Related
-
2009
- 2009-05-07 PE PE2009000633A patent/PE20091830A1/es not_active Application Discontinuation
- 2009-05-07 PA PA20098825701A patent/PA8825701A1/es unknown
- 2009-05-07 JP JP2011507967A patent/JP5611193B2/ja not_active Expired - Fee Related
- 2009-05-07 WO PCT/FR2009/000535 patent/WO2009141532A2/fr active Application Filing
- 2009-05-07 TW TW098115181A patent/TW200951120A/zh unknown
- 2009-05-07 UY UY0001031814A patent/UY31814A/es not_active Application Discontinuation
- 2009-05-07 AR ARP090101646A patent/AR071688A1/es unknown
- 2009-05-07 EP EP09750013A patent/EP2283007A2/fr not_active Withdrawn
-
2010
- 2010-11-09 US US12/942,780 patent/US8680102B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8680102B2 (en) | 2014-03-25 |
| PA8825701A1 (es) | 2009-12-16 |
| JP5611193B2 (ja) | 2014-10-22 |
| TW200951120A (en) | 2009-12-16 |
| EP2283007A2 (fr) | 2011-02-16 |
| WO2009141532A2 (fr) | 2009-11-26 |
| JP2011519905A (ja) | 2011-07-14 |
| FR2930939A1 (fr) | 2009-11-13 |
| WO2009141532A3 (fr) | 2010-02-11 |
| US20110152320A1 (en) | 2011-06-23 |
| PE20091830A1 (es) | 2009-12-21 |
| UY31814A (es) | 2010-01-05 |
| FR2930939B1 (fr) | 2010-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| NO20082976L (no) | Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer | |
| AR045687A1 (es) | Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| EA200701245A1 (ru) | Производные 2,4(4,6)-пиримидинов | |
| TW200738685A (en) | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| NO20063323L (no) | Pyrido- og pyrimidopyrimidinderivater | |
| AR086590A1 (es) | Compuestos de ciclohexanona y herbicidas que los comprenden | |
| EA201200653A1 (ru) | Гетариламинохинолины | |
| AR069740A1 (es) | Compuestos nucleosidos antivirales | |
| DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| ATE478054T1 (de) | Benzimidazolderivate | |
| SG155946A1 (en) | Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| AR044906A1 (es) | Derivados de difenilpiridina, su preparacion y su aplicacion en terapeutica | |
| AR070438A1 (es) | Derivados de 3- aminoalquil -1,3- dihidro -2h indol-2- ona su preparacion y su aplicacion en terapeutica | |
| AR071688A1 (es) | Derivados de pirrol, su preparacion y su aplicacion en terapeutica | |
| CO6551705A2 (es) | Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina | |
| TW200602344A (en) | Novel pyrrolo(2, 3-b)pyridine derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
| AR056874A1 (es) | Derivados de 6- heteroarilpiridoindolona, su preparacion y su aplicacion en terapeutica | |
| AR071483A1 (es) | Derivados de la 1,3- dihidro -2h - pirrolo (3,2-b) piridin-2- ona, su preparacion y sus aplicaciones en terapeutica | |
| AR072540A1 (es) | Derivados de tiofeno-2-carboxamida, su preparacion y su aplicacion en la terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |